Arch Biopartners Inc.
ACHFF · OTC
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.78 | -0.15 | -7.06 | 1.20 |
| FCF Yield | -2.09% | -0.34% | 0.26% | -2.82% |
| EV / EBITDA | 0.00 | -24.45 | -177.10 | -123.80 |
| Quality | ||||
| ROIC | 250.19% | 679.66% | 2,403.41% | -90.91% |
| Gross Margin | -78.04% | -6.50% | -52.14% | -3.86% |
| Cash Conversion Ratio | – | 0.07 | -0.34 | 2.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 30.05% | -20.08% | 142.22% | 245.96% |
| Free Cash Flow Growth | -895.91% | -148.82% | 116.09% | -56.49% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -1.40 | -3.62 | -5.29 |
| Interest Coverage | -10.25 | -9.35 | -4.49 | -4.26 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -72.59 | -13.35 | -88.69 | 119.65 |